IIH diagnosis and vision protection

Idiopathic Intracranial Hypertension (IIH)

Idiopathic Intracranial Hypertension (IIH), historically termed pseudotumour cerebri or benign intracranial hypertension, is a clinical syndrome characterized by elevated intracranial pressure in the absence of a space-occupying lesion, hydrocephalus, or intracranial venous thrombosis.

Epidemiology & Risk Factors

• Demographics: Overwhelmingly affects overweight females of childbearing age (aged 15 to 45 years; female-to-male ratio 8:1; BMI $>30\text{ kg/m}^2$). The annual incidence is approximately 1 to 2 per 100,000 in the general population, but surges to 15 to 20 per 100,000 in obese young women.
• Weight Gain: Recent rapid weight gain (a 5% to 15% increase in total body weight over preceding months) is the most potent trigger.
• Associated Pharmacological Agents: Tetracyclines (minocycline, doxycycline), excess vitamin A and retinoids (isotretinoin), recombinant human growth hormone, anabolic steroids, lithium, and abrupt withdrawal of chronic systemic corticosteroids.

The Modified Dandy Diagnostic Criteria

The diagnosis of IIH requires satisfying all components of the updated Modified Dandy Criteria:

1. Signs and symptoms of raised intracranial pressure (headache, papilloedema, TVOs, pulsatile tinnitus).
2. Absence of localising neurological signs, with the sole exception of unilateral or bilateral cranial nerve VI (abducens) palsy.
3. Completely normal cerebrospinal fluid (CSF) composition (normal protein, glucose, white blood cell count, and cytology).
4. Documented elevated CSF opening pressure measured on lumbar puncture performed in the lateral decubitus position:
   • Adults: $>25\text{ cm H}_2\text{O}$ ($>250\text{ mm H}_2\text{O}$).
   • Children / non-obese: $>28\text{ cm H}_2\text{O}$ in sedated or obese children; $>20-25\text{ cm H}_2\text{O}$ in non-obese children.
5. Normal neuroimaging (MRI brain with contrast and MR Venography [MRV]): exclusion of mass lesions, hydrocephalus, meningeal enhancement, or cerebral venous sinus thrombosis.

Neuroimaging Biomarkers of Raised ICP on MRI / MRV

High-resolution MRI and MRV demonstrate characteristic neuro-radiological signs of elevated ICP in IIH:

• Partially Empty or Empty Sella Turcica: Herniation of the suprasellar CSF-filled arachnoid space through an incompetent diaphragma sellae, flattening the pituitary gland against the sella floor.
• Flattening of the Posterior Sclera / Posterior Globe: Mechanical indentation of the globe at the optic nerve insertion.
• Distension of the Perioptic Subarachnoid Space: Prominent "cuff" of CSF fluid widening the retrobulbar optic nerve sheath.
• Vertical Tortuosity of the Intraorbital Optic Nerve: Redundant, kinked optic nerve course.
• Bilateral Transverse Cerebral Venous Sinus Stenosis: Smooth, tapering narrowing of the distal transverse sinuses on MRV.

Evidence-Based Management of IIH

1. Medical Therapy & Lifestyle Modification

• Structured Weight Loss: Weight reduction is the single disease-modifying intervention. A reduction of 5% to 10% of total body weight routinely induces complete clinical remission, lowering ICP and resolving papilloedema.
• Acetazolamide (Diamox): First-line medical pharmacotherapy, validated by the landmark Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Acetazolamide is an oral carbonic anhydrase inhibitor (CAI) that acts on the choroid plexus epithelium, reducing CSF production by up to 50%. The starting dose is 500 mg to 1,000 mg daily in divided doses, titrated up to 2 to 4 g/day based on tolerance and visual field response. Side effects include distal paraesthesias (fingers and toes), dysgeusia (metallic taste with carbonated drinks), lethargy, hypokalaemia, metabolic acidosis, and nephrolithiasis.
• Topiramate: An antiepileptic agent possessing weak carbonic anhydrase inhibitory properties, coupled with significant appetite suppression that aids weight loss and migraine-like headache prophylaxis; utilized as an alternative or adjunct to acetazolamide.

2. Surgical Interventions for Visual Threat

Surgical intervention is indicated in patients with progressive visual field deterioration despite maximal medical therapy, fulminant IIH (rapid visual acuity and field loss over days), or severe drug intolerance:

1. Optic Nerve Sheath Fenestration (ONSF): Surgical creation of slits or a window in the retrobulbar dural sheath behind the globe, decompressing the perioptic space and allowing CSF egress into the orbital fat. Highly effective for rapid resolution of disc swelling and visual field stabilization; preferred when visual preservation is the primary clinical objective and headaches are mild.
2. CSF diversion: Ventriculoperitoneal or lumboperitoneal shunting can protect vision when intracranial-pressure disease causes deterioration. Severe headache is not a required accompanying feature, and headache alone is generally not an indication. Discuss obstruction, infection, overdrainage and possible revisions with the specialist team.
3. Venous sinus stenting: A selected specialist option after anatomical and physiological assessment. A pressure gradient can inform selection but is not a universal standalone threshold. Evidence limits, antiplatelet requirements and procedural complications must be discussed.

Case: treating pressure while protecting vision

A patient with papilloedema has mild headache but worsening fields. Repeat reliable acuity and field assessment, document the discs, and assess the neurological investigation and pressure diagnosis. Headache severity is not a substitute for visual-risk assessment. A transient improvement after lumbar puncture does not establish durable control or justify repeated punctures as the sole long-term strategy. Medical treatment and weight management address different parts of care, while rapidly threatened vision may need urgent surgical discussion. Follow visual function and disc change closely enough to identify deterioration; avoid interpreting reduced swelling as recovery if optic atrophy is developing. Conversely, headache persisting after papilloedema resolves may need a separate headache plan. The exam answer should identify the immediate visual threat, the secondary causes already excluded and the next action, rather than only naming an intracranial-pressure drug.